FDA committee supports approval of COVID-19 treatment Paxlovid for high-risk adults
The FDA’s Antimicrobial Drugs Advisory Committee voted Thursday to support the approval of Paxlovid for the treatment of mild-to-moderate COVID-19 in adults at high risk for severe disease, hospitalization or death.